AIS Biotech celebrates its first year of existence, and has the honor of being one of the 100 start-ups to invest in, selected by Challenges magazine in 2024!
AIS BIOTECH (for Anti Infective Sugar Biotech) is a start-up created in 2023 from the work of Cermav, granted by the CNRS, the University of Grenoble Alpes and the SATT Linksium.
The company aims to develop a new class of sugar-based anti-infective biotherapeutic products, to contribute to the fight against existing or emerging infections, and antibiotic resistance.
The article is available on the magazine’s website : https://www.challenges.fr/start-up/ais-biotech-developper-des-sucres-qui-soignent-la-grippe_887976
